Prof Benjamin Solomon
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
760 Scholarly works
20 Projects
HIGHLIGHTS
2026
Journal article
Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)
DOI: 10.1016/j.lungcan.2026.1095002026
Journal article
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
DOI: 10.1200/JCO-25-027772026
Journal article
First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need
DOI: 10.1016/j.lungcan.2026.1094712025
Research grants (ARC, NHMRC, MRFF)
Advancing Precision Medicine for Lung Cancer
2020
Journal article
Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma
DOI: 10.1038/s41388-020-1357-62020
Research Grant
PRedicting the Population Health Economic IMpact of Current and New CAncer Treatments (PRIMCAT)
2020
Research grants (ARC, NHMRC, MRFF)
Delivering Personalised Medicine for Lung Cancer
RECENT SCHOLARLY WORKS
2026
Journal article
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
DOI: 10.1093/oncolo/oyag1372026
Journal article
First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C non–small cell lung cancer (NSCLC): Results from the Krascendo-170 study.
DOI: 10.1200/jco.2026.44.16_suppl.85102026
Journal article
Implementing targeted thromboprophylaxis as a supportive care model: Mapping implementation preferences across the cancer care pathway.
DOI: 10.1200/jco.2026.44.16_suppl.e135522026
Journal article
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
DOI: 10.1016/j.lungcan.2026.1093852026
Journal article
Zidesamtinib efficacy and safety in patients with advanced ROS1 -positive solid tumors other than NSCLC in the ARROS-1 study.
DOI: 10.1200/jco.2026.44.16_suppl.31082026
Journal article
Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) chemotherapy in 1L NSCLC.
DOI: 10.1200/jco.2026.44.16_suppl.85132026
Journal article
Value of risk-directed thromboprophylaxis in ambulatory lung and gastrointestinal cancer care: Economic evaluation of the TARGET-TP randomized trial.
DOI: 10.1200/jco.2026.44.16_suppl.12137
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
A vaLue-based Person-Centric Enhanced Health Technology Assessment in CAncer Medicine (ALPACA)